These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9544385)

  • 41. Pathogenesis of Graves' ophthalmopathy.
    Bahn RS; Heufelder AE
    N Engl J Med; 1993 Nov; 329(20):1468-75. PubMed ID: 8413459
    [No Abstract]   [Full Text] [Related]  

  • 42. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
    Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
    Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thyrotropin receptor-DNA vaccination of transgenic mice expressing HLA-DR3 or HLA-DQ6b.
    Pichurin P; Chen CR; Pichurina O; David C; Rapoport B; McLachlan SM
    Thyroid; 2003 Oct; 13(10):911-7. PubMed ID: 14611699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Graves' hyperthyroidism and endocrine ophthalmopathy--one or two closely related diseases?
    Volpé R
    Dev Ophthalmol; 1993; 25():101-11. PubMed ID: 8359344
    [No Abstract]   [Full Text] [Related]  

  • 45. HLA-DR3 transgenic mice immunized with adenovirus encoding the thyrotropin receptor: T cell epitopes and functional analysis of the CD40 Graves' polymorphism.
    Pichurin P; Pham N; David CS; Rapoport B; McLachlan SM
    Thyroid; 2006 Dec; 16(12):1221-7. PubMed ID: 17199432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans.
    Rapoport B; Banuelos B; Aliesky HA; Hartwig Trier N; McLachlan SM
    J Immunol; 2016 Dec; 197(12):4560-4568. PubMed ID: 27913646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of genetic and non-genetic factors in the etiology of Graves' disease.
    Marinò M; Latrofa F; Menconi F; Chiovato L; Vitti P
    J Endocrinol Invest; 2015 Mar; 38(3):283-94. PubMed ID: 25421156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress.
    Heufelder AE
    Eur J Endocrinol; 1995 May; 132(5):532-41. PubMed ID: 7749490
    [No Abstract]   [Full Text] [Related]  

  • 49. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HLA haplotypes and susceptibility to Graves' disease.
    De Rosa G; Testa A; Mariani M; Purpura M; Giacomini D
    Horm Res; 1992; 37(4-5):176-9. PubMed ID: 1490660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease.
    Kim WB; Chung HK; Park YJ; Park DJ; Tahara K; Kohn LD; Cho BY
    Thyroid; 2000 Jul; 10(7):579-86. PubMed ID: 10958310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic determinants of Graves disease.
    Chistyakov DA; Savost'anov KV; Turakulov RI; Nosikov VV
    Mol Genet Metab; 2000; 71(1-2):66-9. PubMed ID: 11001797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA antigens in a family with both parents and several siblings affected by Graves' disease.
    Fernández Castañer M; Potau MA; Reus JC; Ercilla MG
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):535-8. PubMed ID: 6405574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of HLA-DR antigens by thyroid cells: the effect of Graves' IgG.
    Bodolay E; Szegedi G; Suranyi P; Juhasz F; Stenszky V; Balazs C; Farid NR
    Immunol Lett; 1987 May; 15(1):77-81. PubMed ID: 3111991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two major genes, linked to HLA and Gm, control susceptibility to Graves' disease.
    Farid NR; Bear JC
    Nature; 1982 Feb; 295(5850):629. PubMed ID: 6895778
    [No Abstract]   [Full Text] [Related]  

  • 56. [Current understanding of pathogenesis of Graves ophthalmopathy].
    Ando T; Eguchi K
    Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy.
    Baker G; Mazziotti G; von Ruhland C; Ludgate M
    Endocrinology; 2005 Feb; 146(2):835-44. PubMed ID: 15542454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy.
    Burch HB; Sellitti D; Barnes SG; Nagy EV; Bahn RS; Burman KD
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1384-91. PubMed ID: 8200941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema.
    Stadlmayr W; Spitzweg C; Bichlmair AM; Heufelder AE
    Thyroid; 1997 Feb; 7(1):3-12. PubMed ID: 9086563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiomyopathy associated with Graves' disease.
    Koshiyama H; Sellitti DF; Akamizu T; Doi SQ; Takeuchi Y; Inoue D; Sakaguchi H; Takemura G; Sato Y; Takatsu Y; Nakao K
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):111-6. PubMed ID: 8796147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.